JP5602230B2 - スフィンゴシン−１−リン酸受容体アゴニスト - Google Patents

スフィンゴシン−１−リン酸受容体アゴニスト Download PDF

Info

Publication number
JP5602230B2
JP5602230B2 JP2012523967A JP2012523967A JP5602230B2 JP 5602230 B2 JP5602230 B2 JP 5602230B2 JP 2012523967 A JP2012523967 A JP 2012523967A JP 2012523967 A JP2012523967 A JP 2012523967A JP 5602230 B2 JP5602230 B2 JP 5602230B2
Authority
JP
Japan
Prior art keywords
phenyl
oxadiazol
trifluoromethyl
ethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012523967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501729A5 (https=
JP2013501729A (ja
Inventor
ジョン・エル・ギルモア
ジェイムズ・イー・シェペック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013501729A publication Critical patent/JP2013501729A/ja
Publication of JP2013501729A5 publication Critical patent/JP2013501729A5/ja
Application granted granted Critical
Publication of JP5602230B2 publication Critical patent/JP5602230B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012523967A 2009-08-07 2010-08-06 スフィンゴシン−１−リン酸受容体アゴニスト Expired - Fee Related JP5602230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23205409P 2009-08-07 2009-08-07
US61/232,054 2009-08-07
PCT/US2010/044627 WO2011017578A1 (en) 2009-08-07 2010-08-06 Sphingosine-1-phosphate receptor agonists

Publications (3)

Publication Number Publication Date
JP2013501729A JP2013501729A (ja) 2013-01-17
JP2013501729A5 JP2013501729A5 (https=) 2013-08-08
JP5602230B2 true JP5602230B2 (ja) 2014-10-08

Family

ID=43029859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523967A Expired - Fee Related JP5602230B2 (ja) 2009-08-07 2010-08-06 スフィンゴシン−１−リン酸受容体アゴニスト

Country Status (19)

Country Link
US (1) US8399451B2 (https=)
EP (1) EP2462139B1 (https=)
JP (1) JP5602230B2 (https=)
KR (1) KR20120108963A (https=)
CN (1) CN102548989A (https=)
AR (1) AR077819A1 (https=)
AU (1) AU2010279354A1 (https=)
BR (1) BR112012002824A2 (https=)
CA (1) CA2770194A1 (https=)
CL (1) CL2012000326A1 (https=)
CO (1) CO6430439A2 (https=)
EA (1) EA201270266A1 (https=)
ES (1) ES2533095T3 (https=)
MX (1) MX2012001160A (https=)
PE (1) PE20120732A1 (https=)
SG (1) SG177691A1 (https=)
TW (1) TW201109323A (https=)
WO (1) WO2011017578A1 (https=)
ZA (1) ZA201200641B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079734A1 (en) * 2006-10-25 2009-07-22 NeuroSearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
WO2011133734A1 (en) * 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
JP5788507B2 (ja) 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換３−フェニル−１，２，４−オキサジアゾール化合物
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
PY1974248A (es) * 2018-09-13 2020-08-21 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
CN114181276A (zh) * 2021-12-17 2022-03-15 安徽大学 硫酯肽合成方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS6480026A (en) 1987-09-21 1989-03-24 Mitsubishi Electric Corp Resist coater
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US6069143A (en) * 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
AU4064597A (en) 1996-08-16 1998-03-06 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US7479504B2 (en) * 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
ATE448193T1 (de) * 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US20050070506A1 (en) * 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
US7309721B2 (en) * 2002-03-01 2007-12-18 Merck + Co., Inc. Aminoalkylphosphonates and related compounds as Edg receptor agonists
KR101025675B1 (ko) * 2002-04-23 2011-03-30 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
JP4516430B2 (ja) 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール
MXPA05008531A (es) 2003-02-11 2005-11-17 Irm Llc Compuestos biciclicos novedosos y composiciones.
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
CN1791592B (zh) 2003-05-19 2012-07-04 Irm责任有限公司 免疫抑制剂化合物和组合物
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
ES2558761T3 (es) 2003-05-19 2016-02-08 Novartis Ag Compuestos y composiciones inmunosupresores
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
AU2006214314B2 (en) 2005-02-14 2012-02-09 University Of Virginia Patent Foundation Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
US7723378B2 (en) 2005-03-23 2010-05-25 Actelion Pharmaceuticals Ltd. Hydrogenated benzo (C) thiophene derivatives as immunomodulators
BRPI0609668A2 (pt) 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
EP1896446A1 (en) 2005-06-24 2008-03-12 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
WO2007024922A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
TW200800911A (en) 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EP1965807A4 (en) * 2005-11-23 2010-10-27 Epix Delaware Inc S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
JP2009530389A (ja) * 2006-03-21 2009-08-27 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物及びその使用
MX2008012738A (es) 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
US20080070866A1 (en) 2006-08-01 2008-03-20 Praecis Pharmaceuticals Incorporated Chemical compounds
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
AU2007292347A1 (en) 2006-09-07 2008-03-13 Allergan, Inc. Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
TWI392671B (zh) 2006-09-07 2013-04-11 Actelion Pharmaceuticals Ltd 吡啶-４-基衍生物
PE20080769A1 (es) 2006-09-08 2008-08-14 Novartis Ag Derivados de biaril-sulfonamida
ES2400163T3 (es) * 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
MX2009002915A (es) 2006-09-21 2009-03-31 Actelion Pharmaceuticals Ltd Derivados de fenilo y su uso como inmunomoduladores.
RU2009115963A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Производные оксадиазола, обладающие противовоспалительными и иммунодепрессантными свойствами
CA2669102A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
SG177221A1 (en) 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
CL2007003784A1 (es) 2006-12-21 2008-06-27 Abbott Lab Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
PT2125797E (pt) 2007-03-16 2014-03-11 Actelion Pharmaceuticals Ltd Derivados aminopiridina como agonistas do receptor s1p1/edg1
KR20090130062A (ko) * 2007-04-19 2009-12-17 글락소 그룹 리미티드 스핑고신 １―포스페이트 (ｓ１ｐ) 효능제로서 사용하기 위한 옥사디아졸 치환된 인다졸 유도체
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
AU2008306886B2 (en) 2007-10-04 2014-01-16 Merck Serono S.A. Oxadiazole diaryl compounds
ES2622423T3 (es) 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
RU2010121969A (ru) 2007-11-01 2011-12-10 Актелион Фармасьютиклз Лтд (Ch) Новые производные пиримидина
AU2008340113B2 (en) 2007-12-21 2014-01-09 Merck Serono S.A. Triazole oxadiazoles derivatives
SI2291080T1 (sl) 2008-05-14 2015-11-30 The Scripps Research Institute Novi modulatorji sfingosinskih fosfatnih receptorjev
WO2010041655A1 (ja) 2008-10-06 2010-04-15 昭和電工株式会社 触媒およびその製造方法ならびにその用途
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
US8193378B2 (en) 2008-12-05 2012-06-05 Astellas Pharma Inc. 2H-chromene compound and derivative thereof
WO2010069949A1 (en) 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
WO2010072712A1 (en) 2008-12-23 2010-07-01 Novartis Ag Biaryl benzylamine derivatives
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
EP2389377B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP5669363B2 (ja) 2009-03-31 2015-02-12 昭和電工株式会社 樹脂組成物及びこれで処理された紙又は繊維加工品
WO2010113528A1 (en) 2009-04-03 2010-10-07 Panasonic Corporation Mobile communication method, mobile communication system, and corresponding apparatus

Also Published As

Publication number Publication date
US8399451B2 (en) 2013-03-19
PE20120732A1 (es) 2012-06-20
AU2010279354A1 (en) 2012-02-09
CO6430439A2 (es) 2012-04-30
TW201109323A (en) 2011-03-16
CN102548989A (zh) 2012-07-04
ZA201200641B (en) 2013-06-26
CA2770194A1 (en) 2011-02-10
AR077819A1 (es) 2011-09-28
CL2012000326A1 (es) 2012-10-19
JP2013501729A (ja) 2013-01-17
ES2533095T3 (es) 2015-04-07
WO2011017578A1 (en) 2011-02-10
EP2462139A1 (en) 2012-06-13
BR112012002824A2 (pt) 2019-09-24
EA201270266A1 (ru) 2012-07-30
US20110190255A1 (en) 2011-08-04
SG177691A1 (en) 2012-02-28
EP2462139B1 (en) 2015-01-14
MX2012001160A (es) 2012-02-13
KR20120108963A (ko) 2012-10-05

Similar Documents

Publication Publication Date Title
JP5728487B2 (ja) 三環式ヘテロ環化合物
JP5602230B2 (ja) スフィンゴシン−１−リン酸受容体アゴニスト
EP2382212B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
US8389509B2 (en) Substituted pyrazole compounds
EP2389377B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
TW202045498A (zh) 作為法尼醇x受體調節劑之經取代雙環化合物
JP2013544811A (ja) 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物
JP5735634B2 (ja) スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130619

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140819

R150 Certificate of patent or registration of utility model

Ref document number: 5602230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees